Merck & Co’s Keytruda (pembrolizumab) Receives Health Canada’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

 Merck & Co’s Keytruda (pembrolizumab) Receives Health Canada’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Merck & Co’s Keytruda (pembrolizumab) Receives Health Canada’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III KEYNOTE-426 study assessing Keytruda + Inlyta (axitinib) vs Sunitinib as a 1L treatment for patients advanced RCC
  • The P-III KEYNOTE-426 study results: improvement in OS & PFS; 31% reduction in the risk of progression of disease or death; ORR (59% vs 36%); 5yrs. the survival rate for advanced RCC is estimated to be 8%
  • Merck & Co’s (MSD outside the United States and Canada) Keytruda is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Merck & Co 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post